# A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

Source: https://onco.cc/trials/nct07405151/  
OnCo record `nct07405151` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of I-DXd in oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) is a phase 1/2 interventional study registered as NCT07405151 by Merck Sharp & Dohme LLC, with 60 participants planned, started 2026-03-27 and due to reach its primary completion in 2027-06-12. Interventions recorded: I-DXd and Rescue Medication.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07405151
- Phase: 1/2
- Setting: A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07405151: https://clinicaltrials.gov/study/NCT07405151

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07405151.json